Wyeth is now a wholly owned subsidiary of Pfizer

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Wyeth is now a wholly owned subsidiary of Pfizer sits in the top decile of US sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count).

167 total trials none currently recruiting 139 completed early-phase tilt top decile by trial count

Wyeth is now a wholly owned subsidiary of Pfizer: 167 sponsored US clinical trials, none currently recruiting.

Wyeth is now a wholly owned subsidiary of Pfizer sponsors 167 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 139 completed. 53 of these trials are in Phase 3-4 (later-stage) and 102 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 5 trials.

Top-decile sponsor footprint

Wyeth is now a wholly owned subsidiary of Pfizer ranks in the top decile of sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 48/100

139 of 167 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

167 total, page 2 of 4

COMPLETED Phase 1

Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine

NCT00500721
COMPLETED Phase 2

Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease

NCT00481520
COMPLETED Phase 3

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants

NCT00444457
COMPLETED Phase 1

Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement

NCT00454298
COMPLETED Phase 4

Benzocaine Gel Toothache Dose-Response Study

NCT00474175
COMPLETED Phase 1

Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)

NCT00472927
COMPLETED Phase 1

Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients

NCT00479219
COMPLETED Phase 1

Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms

NCT00479778
COMPLETED Phase 1

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects

NCT00458107
COMPLETED Phase 1

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women

NCT00465075
COMPLETED Phase 1

Study Evaluating Drug Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606

NCT00434486
TERMINATED Phase 1

A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

NCT00417677
COMPLETED Phase 1

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

NCT00440427
COMPLETED Phase 1

Study Evaluating AGG-523 in Subjects With Osteoarthritis

NCT00427687
COMPLETED Phase 1

Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential

NCT00427544
COMPLETED Phase 2

A Study of rhBMP-2/CPM in Closed Fractures of the Humerus

NCT00384852
COMPLETED Phase 1

Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart

NCT00447629
COMPLETED Phase 3

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

NCT00366249
TERMINATED Phase 2

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

NCT00425919
TERMINATED Phase 3

Study Evaluating Bifeprunox in Patients With Schizophrenia.

NCT00366327
COMPLETED Phase 1

Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects

NCT00447681
COMPLETED Phase 1

Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis

NCT00440492
COMPLETED Phase 1

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

NCT00406237
COMPLETED Phase 3

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

NCT00406640
COMPLETED Phase 2

Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures

NCT00384358
TERMINATED Phase 1

Study Evaluating SCA-136 Tolerability With Dose Titration and Food

NCT00420706
COMPLETED Phase 1

Study to Evaluate the Effects of Age & Gender on PK, Safety & Tolerability of HCV-796 Administered to Healthy Subjects

NCT00407173
COMPLETED Phase 3

Open Label Extension Study of Bifeprunox

NCT00366171
TERMINATED Phase 2

A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures

NCT00387686
TERMINATED Phase 2

A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee

NCT00396955
TERMINATED Phase 3

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

NCT00366704
COMPLETED Phase 2

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

NCT00367887
COMPLETED

Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density

NCT00418236
COMPLETED Phase 4

Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections

NCT00368537
COMPLETED Phase 3

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

NCT00369343
COMPLETED Phase 4

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

NCT00369382
COMPLETED Phase 3

Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

NCT00366652
COMPLETED Phase 1

Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone

NCT00376324
COMPLETED Phase 3

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT00365300
COMPLETED Phase 1

Study Evaluating LXR-623 in Healthy Subjects

NCT00366522
TERMINATED Phase 2

Study Evaluating the Efficacy of DVS-233 in Fibromyalgia

NCT00301431
COMPLETED Phase 3

Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.

NCT00380224
COMPLETED

Study Evaluating PAZ-417 in Healthy Young/Elderly

NCT00366288
COMPLETED Phase 3

Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD

NCT00362609
COMPLETED Phase 1

Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy

NCT00380900
COMPLETED Phase 3

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

NCT00369434
COMPLETED Phase 1

Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen

NCT00366262
COMPLETED Phase 1

Study Evaluating IMA-638 in Healthy Japanese

NCT00340327
COMPLETED Phase 4

Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program

NCT00401726
COMPLETED Phase 1

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

NCT00319163
← Previous Page 2 of 4 Next →

Phase Distribution

PhaseTrial count
Phase 1 74
Phase 2 28
Phase 3 43
Phase 4 10

Therapeutic Areas

Healthy 5
Gastroesophageal Reflux 2
Depression 2
Skin Diseases, Bacterial 1
Peptic Ulcer Hemorrhage 1
Vaccines, Pneumococcal 1
Bacterial Pneumonia 1
Vasomotor System 1
Pneumococcal Infections 1
Arthritis, Rheumatoid 1

How the Wyeth is now a wholly owned subsidiary of Pfizer early-phase archive is shaped

167 indexed studies, none listed as recruiting (0% open); 139 completed (83%).

Phase mix: 53 late (III/IV) vs 102 early (I/II) (early-phase heavy).

Top condition: Healthy (5 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Wyeth is now a wholly owned subsidiary of Pfizer: archived-pipeline peers nationwide

Peers matched on 167 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Wyeth is now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200 0%5%10%15%20% Total trials Recruiting share Wyeth is now a wholly owned subsidiary of PfizerTeva Branded Pharmaceutical Products R&DAstellas Pharma Global DevelopmentBausch Health AmericasSeattle Children's Hospital10xBio22nd Century Group23andMe3-C Institute for Social Development
Wyeth is now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wyeth is now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 167 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Wyeth is now a wholly owned subsidiary of Pfizer page

167 registered trials is a research-attention snapshot, not an endorsement of Wyeth is now a wholly owned subsidiary of Pfizer or any single study.

  • None of Wyeth is now a wholly owned subsidiary of Pfizer's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Wyeth is now a wholly owned subsidiary of Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Wyeth is now a wholly owned subsidiary of Pfizer pipeline card: 167 registered trials from official public datasets.Report a data error.